




PHARMACEUTICAL 2023

Erasca Inc.
Rank 153 of 446





PHARMACEUTICAL 2023

Erasca Inc.
Rank 153 of 446

The relative strengths and weaknesses of Erasca Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Erasca Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Erasca Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 151%, being 107% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	444,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	48,690
Liabilities, Non-Current	54,366
Other Assets	45,598
Other Compr. Net Income	-879
Other Expenses	102,000
Other Liabilities	0
Other Net Income	4,645
Other Revenues	0
Property and Equipment	24,815
Research and Development	112,457
Selling, General and Administrative Expense	32,993

Output Variable	Value in 1000 USD
Assets	514,909
Liabilities	103,056
Expenses	247,450
Revenues	0
Stockholders Equity	411,853
Net Income	-242,805
Comprehensive Net Income	-243,244
Economic Capital Ratio	151%